Higher self-assessed NYHA class in heart failure patients predicts increased hospitalizations, worse quality of life, and higher mortality rates.

Patients' Self-Assessed Functional Status in Heart Failure by New York Heart Association Class: A Prognostic Predictor of Hospitalizations, Quality of Life and Death

Mavacamten, a first-in-class cardiac myosin inhibitor, effectively reduces symptom severity and improves exercise capacity in patients with symptomatic obstructive hypertrophic cardiomyopathy.

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

The NYHA classification is a valuable clinical tool for adults with congenital heart disease, correlating with exercise limitations, disease severity, and mortality risk, and should be integrated into routine assessment and risk stratification.

New York Heart Association (NYHA) classification in adults with congenital heart disease: relation to objective measures of exercise and outcome

The NYHA classification system poorly discriminates heart failure patients across functional impairment, highlighting the need for improved phenotyping to facilitate risk stratification and response to interventions.

Clinical Implications of the New York Heart Association Classification

Wrist-worn activity trackers show promise in estimating NYHA class and assessing heart failure severity and progression through continuous physical activity monitoring.

Abstract 15451: Using Fitbit Measured Activity Levels as an Indicator of New York Heart Association (nyha) Functional Class

Primary prevention ICDs reduce mortality in NYHA class II patients and show a trend toward reducing mortality in NYHA class III patients, but improved risk stratification tools are needed for better patient selection and shared decision-making.

New York Heart Association class and the survival benefit from primary prevention implantable cardioverter defibrillators: A pooled analysis of 4 randomized controlled trials

Ambulatory class IV heart failure patients receiving CRT have inferior long-term outcomes compared to those with class III symptoms, but survival in these patients continues to parallel class III patients over extended follow-up.

Long-term outcomes in patients with ambulatory new york heart association class III and IV heart failure undergoing cardiac resynchronization therapy.

Higher NYHA class is associated with poor outcomes in stage C and D heart failure patients, but no significant transition to lower NYHA class occurs with pharmacotherapy in a tertiary level hospital.

Frequency of Transition of patients with NYHA class III / IV to NYHA class I / II / III of stage C and D Heart Failure with Pharmacotherapy in a Tertiary Level Hospital

Mood symptoms in coronary heart disease patients are largely influenced by the disease itself, with education background playing a greater role when the patient's condition is unstable.

Associations of mood symptoms with NYHA functional classes in angina pectoris patients: a cross-sectional study

The NYHA classification has a general inverse correlation with peak oxygen consumption (pVO2), but significant heterogeneity exists across studies within each NYHA class, potentially limiting direct comparison across studies.

Correlation of the New York Heart Association classification and the cardiopulmonary exercise test: A systematic review.

A standardized questionnaire can accurately determine New York Heart Association classification in multicenter trials without blinded conditions, with good reproducibility.

Development and validation of a patient questionnaire to determine New York Heart Association classification.

ICD efficacy is greater in patients with NYHA I/II vs. III/IV limitations, but other heart failure interventions show no clear evidence supporting using NYHA class as a rigid criterion for selecting therapies.

Baseline Functional Class and Therapeutic Efficacy of Common Heart Failure Interventions: A Systematic Review and Meta-analysis.

CRT implantation in NYHA class IV patients leads to better symptomatic improvement and reduced all-cause mortality compared to NYHA class III patients, but higher all-cause mortality.

One-year outcome after CRT implantation in NYHA class IV in comparison to NYHA class III patients

Long-term survival in patients with primary pulmonary hypertension treated with epoprostenol depends on baseline severity and response to therapy, with lung transplantation considered in those who remain in functional class III or IV or do not achieve significant hemodynamic improvement after three months.

Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival.

Older patients are assigned higher NYHA classes irrespective of patient-reported health status, but no differences were found by race, sex, education, or BMI.

Abstract 13085: Sociodemographic Predictors of NYHA Class Assignment: An Analysis From CHAMP-HF

A worse NYHA functional class is associated with higher all-cause and CV-related healthcare resource utilization and costs in patients with obstructive hypertrophic cardiomyopathy.

Abstract 12315: Healthcare Resource Utilization and Costs Associated With New York Heart Association Functional Class in Patients With Obstructive Hypertrophic Cardiomyopathy in the United States

Baseline NYHA class IV in TAVI candidates increases mortality risk within 3 months, but long-term outcomes are comparable to those of patients in Class III and less.

Comparison of Early and Long-Term Outcomes After Transcatheter Aortic Valve Implantation in Patients with New York Heart Association Functional Class IV to those in Class III and Less.

Terminalia Arjuna bark extract (500 mg 8-hourly) improves symptoms and signs of heart failure in patients with severe refractory heart failure, leading to improved quality of life.

Salutary effect of Terminalia Arjuna in patients with severe refractory heart failure.

The NYHA functional classification system is a valid measure of functional status in cardiac patients, but its reproducibility and reliability remain inconclusive.

Validity and reliability of the NYHA classes for measuring research outcomes in patients with cardiac disease.

The NYHA classification for heart failure is a poor discriminator of cardiopulmonary capacity among patients with mild heart failure, raising questions about its use as a benchmark for guiding therapy.

Reassessing the NYHA classification for heart failure: a comparison between classes I and II using cardiopulmonary exercise testing

These studies suggest that NYHA class III is associated with increased hospitalizations, worse quality of life, higher mortality rates, and poor outcomes in heart failure patients, while some studies suggest that interventions like mavacamten and primary prevention ICDs may improve symptoms and exercise capacity.